Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc. (AXSM)
:AXSM
Holding AXSM?
Track your performance easily
AXSM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$64.11 - $105.00
Previous CloseN/A
Volume140.83K
Average Volume (3M)810.42K
Market Cap
$4.46B
Enterprise Value$4.19B
Total Cash (Recent Filing)$36.62M
Total Debt (Recent Filing)$9.47M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Mar 03, 2025EPS Estimate
-0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.54
Shares Outstanding48,462,376
10 Day Avg. Volume989,024
30 Day Avg. Volume810,420
Standard Deviation0.22
R-Squared0.06
Alpha0.00619
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)13.16
Price to Cash Flow (P/CF)-59.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue12.38
Enterprise Value/Gross Profit17.14
Enterprise Value/Ebitda-14.32
Forecast
1Y Price Target
$137.36Price Target Upside49.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Axsome Therapeutics News
Bulls Say, Bears Say
Bulls Say
Market CompetitionNegative P3 KOASTAL-1 study data for Neumora Therapeutics' navacaprant in major depressive disorder could be a positive for Auvelity, given the removal of a direct competitor in MDD.
Regulatory ApprovalManagement remains confident in the ability to progress AXS-05 in Alzheimer's disease agitation towards a successful filing and approval, and reiterated plans to submit an NDA.
Sales GrowthThe newly added salesforce is expected to be deployed by the end of January, and management anticipates an uplift to Auvelity's prescription trajectory in the coming months as a result.
Bears Say
Clinical Trial ResultsADVANCE-2 provided a negative surprise with placebo outperformance and a lower treatment effect compared to ADVANCE-1.
Prescription PerformanceWeekly prescription data for Auvelity showed no growth in TRx and NRx, indicating flat performance.
Regulatory ApprovalAXSM shares are perceived as weak possibly due to a later than expected NDA which risks pushing out ADA approval and launch catalyst events to 2026.
---
Ownership Overview
1.42% Insiders
19.13% Mutual Funds
0.24% Other Institutional Investors
65.93% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AXSM FAQ
What was Axsome Therapeutics Inc.’s price range in the past 12 months?
Axsome Therapeutics Inc. lowest stock price was $64.11 and its highest was $105.00 in the past 12 months.
What is Axsome Therapeutics Inc.’s market cap?
Axsome Therapeutics Inc.’s market cap is $4.46B.
When is Axsome Therapeutics Inc.’s upcoming earnings report date?
Axsome Therapeutics Inc.’s upcoming earnings report date is Mar 03, 2025 which is in 41 days.
How were Axsome Therapeutics Inc.’s earnings last quarter?
Axsome Therapeutics Inc. released its earnings results on Nov 12, 2024. The company reported -$1.34 earnings per share for the quarter, beating the consensus estimate of -$1.383 by $0.043.
Is Axsome Therapeutics Inc. overvalued?
According to Wall Street analysts Axsome Therapeutics Inc.’s price is currently Undervalued.
Does Axsome Therapeutics Inc. pay dividends?
Axsome Therapeutics Inc. does not currently pay dividends.
What is Axsome Therapeutics Inc.’s EPS estimate?
Axsome Therapeutics Inc.’s EPS estimate is -0.96.
How many shares outstanding does Axsome Therapeutics Inc. have?
Axsome Therapeutics Inc. has 48,462,376 shares outstanding.
What happened to Axsome Therapeutics Inc.’s price movement after its last earnings report?
Axsome Therapeutics Inc. reported an EPS of -$1.34 in its last earnings report, beating expectations of -$1.383. Following the earnings report the stock price went up 9.354%.
Which hedge fund is a major shareholder of Axsome Therapeutics Inc.?
Among the largest hedge funds holding Axsome Therapeutics Inc.’s share is Fairmount Funds Management Llc. It holds Axsome Therapeutics Inc.’s shares valued at 212M.
---
Axsome Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$137.36 (49.40% Upside)
$137.36 (49.40% Upside)
Blogger Sentiment
Bullish
AXSM Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 571.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 17.1%
Last 30 Days ▲ 17.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.55%
12-Months-Change
Fundamentals
Return on Equity
-171.61%
Trailing 12-Months
Asset Growth
-6.56%
Trailing 12-Months
Company Description
Axsome Therapeutics Inc.
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
---
AXSM Company Deck
---
AXSM Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted robust revenue growth and strong sales performance for key products, alongside significant progress in the pipeline. Despite increased costs and a net loss, the strong cash position and strategic advancements suggest a positive outlook.Read More>---
AXSM Stock 12 Month Forecast
Average Price Target
$137.36
▲(49.40% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Intra-Cellular Therapies
―
Innoviva
―
ACADIA Pharmaceuticals
―
Cytokinetics
―
Xencor
―
Best Analysts Covering AXSM
1 Year
1 Year Success Rate
16/19 ratings generated profit
1 Year Average Return
+41.73%
reiterated a buy rating 9 days ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 84.21% of your transactions generating a profit, with an average return of +41.73% per trade.
---